In recent decades, the emphasis of biomarker research has centered around blood-based markers.
Evonik lays off 2,000 staffers; EurekaBio gets $40M for viral vector production; Sarepta unfazed by Novo-Catalent deal
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential updates on new builds, collaborations, recalls and more. Evonik has cut 2,000 staff members